Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren's Disease.
Sarthak GuptaEiko YamadaHiroyuki NakamuraPaola PerezThomas J F PranzatelliKalie DominickShyh-Ing JangMehdi AbedDaniel MartinPeter BurbeloChangyu ZhengBen FrenchIlias AlevizosZohreh KhavandgarMargaret BeachEileen PelayoBrian WalittSarfaraz HasniMariana J KaplanMayank TandonM Teresa MagoneDavid E KleinerJohn A ChioriniAlan N BaerBlake M WarnerPublished in: medRxiv : the preprint server for health sciences (2023)
SjD lacks an approved, efficacious and targeted therapy. Several large clinical trials have been unsuccessful due in part to a lack of biologically relevant endpoints or predictive biomarkers. We establish a multimodal testing platform using human tissues from SjD patients to identify actionable targets and to directly test treatment effects. Our data suggest that blocking the IFN-JAK-STAT pathway by using JAKi is a rational therapy for SjD. Moreover, these data can also serve as biological endpoints for clinical trials [ NCT04496960 ].
Keyphrases
- clinical trial
- end stage renal disease
- electronic health record
- chronic kidney disease
- ejection fraction
- dendritic cells
- endothelial cells
- newly diagnosed
- oxidative stress
- gene expression
- big data
- immune response
- prognostic factors
- randomized controlled trial
- high throughput
- pain management
- rheumatoid arthritis
- machine learning
- patient reported outcomes
- data analysis
- patient reported
- systemic lupus erythematosus
- deep learning
- study protocol
- double blind